Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

FDA's Rigor May Boost Sales

By Brian Orelli, PhD - Updated Nov 14, 2016 at 11:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The confidence gained from stricter rules could translate into more prescriptions.

FDA changes to the labeling of drugs are rarely a good thing for the companies that make and sell them -- just look at the black-box warning for GlaxoSmithKline's (NYSE:GSK) Avandia as a recent example. But one of the FDA's most recent changes might actually increase sales.

The FDA announced yesterday that it was updating the labeling of Bristol-Myers Squibb's (NYSE:BMY) blood-thinning drug Coumadin to indicate that a patient's genetic makeup may affect how he responds to the drug. The manufacturers of generic warfarin will also have to change their packaging.

The new packaging will now recommend to doctors that patients have a genetic test to determine if they carry variations in two specific genes that would predispose them to bleeding caused by warfarin. As many as one-third of patients may have a genetic variation that causes the drug to be metabolized differently than the general population.

In the immediate future, the change might have a negative effect on sales. Many insurers, such as Aetna (NYSE:AET) and WellPoint (NYSE:WLP), currently won't pay for the $300-$500 genetic test because it hasn't been proven to be cost-effective. That additional out-of-pocket cost might discourage people from taking the drug. But I think the insurance companies will eventually come around. After all, warfarin is the second-most-likely drug in the U.S. to cause side effects that require a trip to the emergency room. (Insulin is No. 1.)

The large variation in the doses needed to give patients safe and effective treatment has probably already discouraged some doctors from prescribing warfarin. Making the genetic test -- and the formulas to determine proper dosage -- widely available will ultimately give doctors greater confidence to prescribe the drug.

One clear winner in the FDA decision is the lab testing companies, including Laboratory Corporation of America (NYSE:LH), which offers the warfarin genetic test, and Quest Diagnostics (NYSE:DGX), which plans to introduce one soon.

The FDA currently has genetic variation recommendations on four other drugs, including Pfizer's (NYSE:PFE) cancer-fighting Camptosar. I think it's likely we'll continue to see increased emphasis by the FDA on personalized medicine. That should be a boon to the lab testing companies, and I don't think it's necessarily bad for the drug companies. After all, patients will need to take some kind of drug for their ailment; the genetic tests will just tell them which drug, and how much of it, to take.

Quest Diagnostics and Pfizer are picks of the Inside Value newsletter. Glaxo was picked by our Income Investor team and Laboratory Corp. was recommended by the Stock Advisor newsletter.

Not sure which newsletter to pick? Click here to take a free 30-day test drive of any of our newsletters.

Fool contributor Brian Orelli, Ph.D., has genotyped more mice than he cares to discuss, but never any humans. He doesn't own shares of any company mentioned in this article. The Fool's disclosure policy is type AB-, the most rare indeed.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$56.83 (0.91%) $0.51
Aetna Inc. Stock Quote
Aetna Inc.
AET
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.48 (-5.14%) $-2.79
GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
GSK
$41.76 (1.24%) $0.51
Anthem, Inc. Stock Quote
Anthem, Inc.
ANTM
$403.62 (2.18%) $8.62
Quest Diagnostics Incorporated Stock Quote
Quest Diagnostics Incorporated
DGX
$157.64 (0.37%) $0.58
Laboratory Corporation of America Holdings Stock Quote
Laboratory Corporation of America Holdings
LH
$289.26 (-0.36%) $-1.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.